CA-CROWN-BIOSCIENCE
Crown Bioscience (CrownBio), a JSR Life Sciences company and leader in preclinical services that help biopharmaceutical companies accelerate new drug development programs, has acquired OcellO B.V., a privately owned contract research organization located in the Netherlands. Through the acquisition, CrownBio will expand its portfolio of in vitro services, integrating OcellO’s expertise in high content imaging alongside CrownBio’s in vitro and in vivo screens and immunotherapy assessment services. Financial terms are not being disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005619/en/
“CrownBio and OcellO believe that the key to improving clinical research success is to utilize more patient-relevant models and assays that can generate reliable efficacy data as early as possible in the drug development process,” said Armin Spura, PhD, Chief Executive Officer of CrownBio . “This acquisition brings together the complementary strengths of our two companies, enhancing our in vitro services portfolio and offering customers the ability to better evaluate multiple drug combinations and targets, across a wider range of tumor and cancer types, with improved predictability and clinical relevance moving from in vitro to in vivo phases of drug discovery.”
The acquisition establishes CrownBio as the only global source licensed to offer customers specialized Hubrecht Organoid Technology (HUB) for drug development programs. Under the terms of the agreement, Leo Price, PhD, OcellO’s Chief Executive Officer and Chief Scientific Officer, will join CrownBio as Senior Vice President, In Vitro , to lead the Company’s in vitro business in the US and Europe.
“I am delighted to join CrownBio and help grow the company’s in vitro portfolio,” said Dr. Price. “We will continue our shared heritage of innovation and dedication to customer service to serve complex needs in early-stage cancer drug development. Our combined expertise is particularly suited for disease-relevant large-scale screening, allowing our customers to evaluate multiple drug combinations in a rapid, scientifically rigorous, and cost-effective way.”
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, immuno-oncology and inflammatory disorders. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit: www.crownbio.com
About OcellO B.V.
OcellO is a leading provider of compound testing services using advanced organotypic human tissue models of cancer, inflammation, and polycystic kidney disease. Automated 3D cell culture technology is combined with high content 3D imaging and analysis in a robust platform that provides scalability without compromising biological complexity. Cancer drug discovery services utilize organoids, PDX- derived tumoroids and patient tumor-derived models representing most solid tumor types and incorporating different components of the immune system.
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005619/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Coca-Cola Company and Gutsche Family Investments Agree to Sell Controlling Interest in Coca-Cola Beverages Africa to Coca-Cola HBC AG21.10.2025 08:00:00 CEST | Press release
The Coca-Cola Company and Gutsche Family Investments have agreed to sell a 75% controlling interest in Coca-Cola Beverages Africa Pty. Ltd. to Coca-Cola HBC AG, the companies announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020939952/en/ CCBA is the largest Coca-Cola bottler in Africa. It operates in 14 countries on the continent and accounts for about 40% of all Coca-Cola product volume sold across Africa. Coca-Cola HBC is one of the largest Coca-Cola bottlers in the world, with operations in 29 countries across Europe and Africa, including Nigeria and Egypt. Coca-Cola will sell 41.52% out of its 66.52% stake in CCBA to Coca-Cola HBC, and Coca-Cola HBC is acquiring 33.48% of CCBA that is held by GFI. In total, the transaction values 100% of CCBA at an equity value of US$3.4 billion. The transactions are targeted to close by the end of 2026. Coca-Cola and Coca-Cola HBC have also agreed to a separate option
Baszucki Group Announces Six Recipients of the Metabolic Psychiatry Scholar Award for Emerging Scientific Leaders Advancing Mental Health Innovation21.10.2025 08:00:00 CEST | Press release
Six early-career scientists and clinicians will receive $150,000 each to conduct research on metabolic therapies for mental health Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award, a new initiative that supports exceptional early-career scientists and clinicians working to advance understanding of the connection between metabolic health and mental health. The award represents a significant step forward in growing the rapidly advancing field of metabolic psychiatry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020666940/en/ Baszucki Group 2025 Metabolic Psychiatry Scholar Award Recipients The six scholars will each receive up to $150,000 over 18 months for original research in metabolic psychiatry. The award program advances Baszucki Group’s mission to transform mental health outcomes through research at the intersection of metabolism, psychiatry, and neuroscienc
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer21.10.2025 07:17:00 CEST | Press release
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer (mCRPC) No dose-limiting toxicities and no treatment-related serious adverse events observed Xerostomia predominantly Grade 1 80% PSA50 response at doses ≥ 160 MBq 100% objective response rate (ORR) in patients with RECIST-measurable lesions, including two complete responses (CRs) The data represent the first clinical trial results for a Lead-212 (212Pb)-based PSMA-targeted radioligand therapy and highlight the potential of 212Pb-ADVC001 to enhance therapeutic options for patients with prostate cancer Phase 2 expansion will evaluate 160 MBq and 200 MBq of 212Pb-ADVC001 using a randomized multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes in three indications: mCRPC (chemo-naïve, and post-177Lu-PSMA) and hormone-sensitive prostate cancer (mHSPC) AdvanCell, a clin
GigaDevice Deepens Commitment to Japan, Advancing Local Services and Global Collaboration21.10.2025 05:57:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has officially opened its new office in Minato City, Tokyo. This milestone reflects the company’s deepening commitment to the Japanese market and marks a significant step in enhancing local customer support, strengthening regional collaboration, and advancing its global development efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020247226/en/ GigaDevice executives and employees celebrate the opening of the new Japan office in Minato City, Tokyo. Japan has long served as a vital pillar of GigaDevice’s global strategy. Over the years, the company has expanded its local team, refined operation to meet evolving customer needs, and established a responsive professional service system. This new office will further enhance GigaDevice’s technical responsiveness and agility, foster closer
Streamlining Project Efficiency with Murata’s Pre-Installed Electrical Models in the Latest Versions of Cadence OrCAD X Capture™, Allegro X System Capture™ and AWR Design Environment™ (Microwave Office)21.10.2025 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces a significant collaboration with Cadence Design Systems, Inc., making product libraries directly accessible within Cadence’s leading Electronic Design Automation (EDA) tools. Murata’s selected inductor and capacitor products are now pre-installed in the latest versions of Cadence OrCAD X Capture™, Allegro X System Capture™ and AWR Design Environment™ (Microwave Office). By enabling engineers to select Murata components directly within these tools and run simulations, this initiative is set to refine circuit design and streamline the design process for power supply, high-frequency, and noise suppression circuits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020071479/en/ [Murata Manufacturing Co., Ltd.] Collaboration with Cadence Design Systems, Inc. Advancements in IC performance and increased circuit complexity on PCBs are driving the industry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom